ADI-001
- Generic Name
- ADI-001
A Phase 1 Study of ADI-001 in Autoimmune Disease
Phase 1
Recruiting
- Conditions
- Lupus NephritisIdiopathic Inflammatory MyopathiesAutoimmune DiseasesSystemic Sclerosis (SSc)ANCA-Associated Vasculitis (AAV)Systemic Lupus Erythematosus (SLE)Stiff Person Syndrome
- Interventions
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Adicet Therapeutics
- Target Recruit Count
- 180
- Registration Number
- NCT06375993
- Locations
- 🇺🇸
The Feinstein Institutes for Medical Research - Northwell Health, Manhasset, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath